Health Economics Of Personalized Medicine: Cost-Effectiveness And Value Assessment — A Systematic Review.

Abstract

Background: Personalized medicine is an evolving approach in healthcare that tailors medical treatment to the individual characteristics of each patient, including their genetic makeup, environment, and lifestyle. This approach aims to improve patient outcomes by providing more effective treatments while minimizing adverse reactions. As personalized medicine continues to gain traction, evaluating its cost-effectiveness and overall value is crucial for its integration into healthcare systems. This paper systematically reviews the existing literature on the health economics of personalized medicine, focusing on its cost-effectiveness and value assessment.

Objective:The primary objective of this study is to critically evaluate the economic impact, cost-effectiveness, and value assessment of personalized medicine. By reviewing a range of peer-reviewed articles, the study seeks to offer a comprehensive understanding of how personalized medicine affects healthcare costs and patient outcomes. The review aims to identify key factors that contribute to the economic feasibility of personalized treatments, as well as barriers to their widespread implementation.

Methods: A systematic review approach was adopted, in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, to ensure a structured and transparent analysis. A thorough search was conducted across multiple databases, including PubMed, Google Scholar, Scopus, and Web of Science, using specific keywords related to personalized medicine, cost-effectiveness, and value assessment. The selection criteria focused on peer-reviewed articles published from 2019 onwards, emphasizing studies that evaluated the economic implications of personalized medicine in clinical settings.

Results: The review identified several studies that assessed the cost-effectiveness of personalized medicine, particularly in the areas of oncology, pharmacogenomics, and genomic medicine. The majority of studies indicated that personalized treatments have the potential to reduce healthcare costs by minimizing adverse drug reactions, improving patient outcomes, and reducing hospital readmissions. However, high initial costs and limited access to diagnostic technologies were cited as significant barriers to the widespread adoption of personalized medicine. Furthermore, the economic value of personalized medicine was often evaluated through a combination of clinical outcomes and economic analysis.

Conclusions: The findings suggest that while personalized medicine holds considerable promise in improving patient care and reducing healthcare costs, its widespread implementation faces several challenges, including high upfront costs, limited clinical evidence, and infrastructural barriers. Policymakers and healthcare providers must consider these factors when evaluating the adoption of personalized medicine within healthcare systems. Future research should focus on the long-term cost-effectiveness of personalized treatments and explore strategies to overcome existing barriers.